From Mechanism to Longevity: Redefining the Future of Aging
We leverage Mechanism of Action (MoA) to develop bona fide gerotherapies—targeting aging at its core to extend health-span and longevity.
Aging is the #1 risk factor for most common diseases.
The list includes cancer, infectious, metabolic, and neurodegenerative diseases. A gerotherapy is a drug that addresses an underlying core aging molecular mechanism. Because there are multiple factors that contribute to aging, targeting them precisely is critical.
MOAT: a MoA-driven clinical indication prediction engine.
MOAT (mechanism of action technologies) combines both experimental and computational approaches. The strengths of our approach are twofold, both reinforcing our focus on drug efficacy—a key factor in preventing therapeutic failure.
First, ensuring an accurate understanding of a small molecule’s MoA is vital to establishing contexts in which it might be effective and what its side effect liabilities might be.
Second, by ensuring the compounds we advance are bona fide gerotherapies, we ensure a ‘pipeline in a pill’ - where each asset can be used in multiple clinical indications.
Pioneering the future of metabolic disease treatment.
BIOIO is focusing on therapies for diabetes and its consequences. By targeting two crucial metabolic pathways—fatty acid oxidation and sphingolipid biosynthesis—BIOIO aims to develop effective, first-in-class treatments, both standalone therapies and genetically informed combination strategies, to combat metabolic disease. Our targets, the NMNAT-SIRT axis and SPT, are strongly associated with prolonged health-span.
